Pneumococcal conjugate second or third-dose vaccines (PCVc) in Trinidad and Tobago
Trinidad and Tobago: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 97.0% in 2025. β Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Trinidad and Tobago, 2008β2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Trinidad and Tobago is 97.0%, measured in 2025.
That represents a change of up 6.6% on the previous year and up 5.4% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Trinidad and Tobago peaked at 99.0% in 2018 and was at its lowest, 0.0%, in 2008.
Trinidad and Tobago ranks 17th of 194 countries on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 68.4% | 0.0% | 99.0% | 10 |
| 2020s | 94.3% | 91.0% | 97.0% | 6 |
Countries ranked near Trinidad and Tobago
More health data for Trinidad and Tobago
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.1463 % change on previous year (2090)
- Heat deaths vs projected death rates 1,638 (2090)
- Un projection of annual infant deaths 24 (2100)
- Population ages 65 and above, total, annual growth rate 4.38 % change on previous year (2025)
- Population ages 65 and above, total, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 65 and above, total, per capita 0.1293 units per person (2025)
- Population, female, annual growth rate 0.0254 % change on previous year (2025)
- Population, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population, female, per capita 0.506 units per person (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Trinidad and Tobago?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Trinidad and Tobago was 97.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Trinidad and Tobago?
- The highest recorded value was 99.0% in 2018.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Trinidad and Tobago?
- The lowest recorded value was 0.0% in 2008.
- How does Trinidad and Tobago rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Trinidad and Tobago ranks 17th out of 194 countries with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Trinidad and Tobago?
- Over the last ten years it is up 5.4%. The long-run trend across the full record is volatile.
- Where does this Trinidad and Tobago data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV Β· JSON β 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).